Olegra 50 mg FC tablet
PDF Leaflet Revision Date: 01 January 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in adults.
Dosage (summary)
50 mg once daily for treatment-nau00efve; 50 mg twice daily for integrase inhibitor resistant.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Risk of neural tube defects; avoid breastfeeding.
Key Drug Interactions
- Dofetilide
- Metformin
- Rifampicin
- Etravirine
- Efavirenz
Contraindications
- Hypersensitivity to dolutegravir
- Moderate/severe hepatic impairment
- Co-administration with dofetilide
Common side effects
- Nausea
- Diarrhoea
- Fatigue
- Rash
- Insomnia
Counselling Points
- Take with or without food
- Monitor for signs of hypersensitivity
- Discuss pregnancy risks with women of childbearing potential
Serious warnings
- Hypersensitivity reactions
- Immune Reconstitution Syndrome
- Osteonecrosis
Important Disclaimer
The Olegra 50 mg FC tablet professional information leaflet below is the property of Aurobindo Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
